IONS

86.32

3.77% 3.14

Dopo l'orario di chiusura: 86.28 -0.04 -0.05%

Ionis Pharmaceuticals Inc (IONS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$83.18

Aprire:

$84.42

Volume 24 ore:

2.36M

Relative Volume:

1.29

Capitalizzazione di mercato:

$14.27B

Reddito:

$1.06B

Utile/perdita netta:

$-326.58M

Rapporto P/E:

-41.06

EPS:

-2.1022

Flusso di cassa netto:

$-977.73M

1 W Prestazione:

+8.87%

1M Prestazione:

+15.90%

6M Prestazione:

+3.79%

1 anno Prestazione:

+106.61%

Intervallo 1D:

$82.95

$86.67

Intervallo di 1 settimana:

$77.95

$86.67

Portata 52W:

$40.03

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Nome

Ionis Pharmaceuticals Inc

Settore

Healthcare (1094)

Industria

Biotechnology (615)

Telefono

(760) 931-9200

Indirizzo

2855 GAZELLE COURT, CARLSBAD, CA

Dipendente

1,402

Cinguettio

@ionispharma

Prossima data di guadagno

2026-07-29

Ultimi documenti SEC

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IONS Ionis Pharmaceuticals Inc	86.32	13.75B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.93	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.50	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-21	Iniziato	Canaccord Genuity	Buy
2026-04-10	Ripresa	Raymond James	Outperform
2026-01-28	Ripresa	Barclays	Overweight
2025-10-08	Aggiornamento	JP Morgan	Neutral → Overweight
2025-09-26	Aggiornamento	Goldman	Sell → Neutral
2025-09-03	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2025-07-31	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-07-01	Aggiornamento	Barclays	Equal Weight → Overweight
2025-04-07	Iniziato	H.C. Wainwright	Buy
2025-03-31	Iniziato	Redburn Atlantic	Neutral
2024-08-02	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-07-16	Ripresa	Jefferies	Buy
2024-06-14	Aggiornamento	Bernstein	Underperform → Mkt Perform
2024-04-10	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2024-01-02	Aggiornamento	BofA Securities	Neutral → Buy
2023-10-23	Aggiornamento	BofA Securities	Underperform → Neutral
2023-09-29	Iniziato	Raymond James	Strong Buy
2023-07-31	Aggiornamento	Citigroup	Neutral → Buy
2023-06-07	Ripresa	Piper Sandler	Overweight
2023-05-04	Aggiornamento	Citigroup	Sell → Neutral
2023-03-21	Iniziato	Bernstein	Underperform
2022-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Ripresa	Morgan Stanley	Overweight
2022-07-18	Ripresa	Oppenheimer	Outperform
2022-03-31	Ripresa	Piper Sandler	Overweight
2022-03-01	Iniziato	Citigroup	Sell
2022-03-01	Iniziato	Guggenheim	Buy
2022-02-01	Downgrade	BofA Securities	Buy → Underperform
2021-12-14	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-05-07	Aggiornamento	UBS	Sell → Neutral
2021-03-01	Aggiornamento	Barclays	Underweight → Equal Weight
2020-12-16	Iniziato	UBS	Sell
2020-12-15	Aggiornamento	Cowen	Market Perform → Outperform
2020-09-14	Ripresa	JP Morgan	Neutral
2020-09-02	Iniziato	The Benchmark Company	Hold
2020-06-01	Ripresa	Oppenheimer	Outperform
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-03-05	Iniziato	Citigroup	Buy
2019-12-13	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-11-07	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Aggiornamento	Bernstein	Mkt Perform → Outperform
2018-08-08	Reiterato	Stifel	Hold
2018-08-07	Reiterato	Stifel	Hold
2018-05-08	Downgrade	Evercore ISI	Outperform → In-line
2017-10-06	Ripresa	Goldman	Sell
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-08-09	Reiterato	Stifel	Hold
2017-03-10	Downgrade	Goldman	Neutral → Sell
2016-12-28	Reiterato	BMO Capital Markets	Outperform
2016-12-27	Reiterato	Leerink Partners	Mkt Perform

Mostra tutto

Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie

12:28 PM

IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study - Yahoo Finance

12:28 PM

11:39 AM

Ionis Pharmaceuticals stock leans on pipeline and Nasdaq trading - AD HOC NEWS

11:39 AM

08:40 AM

Novartis’ Pipeline Building Continues, Pelacarsen Readout Coming Soon (NYSE:NVS) - Seeking Alpha

08:40 AM

06:42 AM

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.

06:42 AM

05:04 AM

Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment - Clinical Trials Arena

05:04 AM

Jul 06, 2026

Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com

Jul 06, 2026

Ionis Pharmaceuticals director Joseph Klein III sells $910k in stock - Investing.com Canada

Jul 06, 2026

Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Ionis Pharmaceuticals Advances Obudanersen for Angelman Syndrome - GuruFocus

Jul 06, 2026

Ionis finishes patient enrollment in Phase 3 rare disease trial - grafa.com

Jul 06, 2026

Ionis Pharmaceuticals, Inc. Completes Enrollment in Pivotal Cohort of Phase 3 REVEAL Study Evaluating Obudanersen in Angelman Syndrome - marketscreener.com

Jul 06, 2026

Ionis Pharmaceuticals (IONS) Advances Phase 3 REVEAL Study for A - GuruFocus

Jul 06, 2026

Ionis completes enrollment in Angelman syndrome drug trial By Investing.com - Investing.com Canada

Jul 06, 2026

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome - Business Wire

Jul 06, 2026